ResearcherHenry Ford HealthActive in the last 2 years
P. A. Philip
Matched on OpenAlex author ID A5111702896. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 60
2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers
Papers 8
- XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218804↗
- Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence. Co-author DOI 10.1038/s41698-026-01543-6↗
- Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
- Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.11.21.689857↗
- Morphomics, Survival, and Metabolites in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2024.40047↗
- Targeting B cells in pancreatic adenocarcinoma: does RESOLVE resolve the question? Co-author DOI 10.1016/j.annonc.2021.02.009↗
- MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Last author DOI 10.1038/bjc.2012.383↗
- Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Co-author DOI 10.1093/carcin/bgs189↗
Closest collaborators
The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sahar F. Bannoura · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Bin Bao · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Md. Hafiz Uddin · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Boris Pasche · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Husain Yar Khan · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Eliza Wright Beal · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Amro Aboukameel · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Muhammad Wasif Saif · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Ramzi M. Mohammad · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Anthony Frank Shields · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Azeddine Atfi · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Asfar Sohail Azmi · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Bassel F. El‐Rayes · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Harshabad Singh · 1 shared paper, 2026 · strength 0.24
- Sebastian Cole · 1 shared paper, 2026 · strength 0.24
- David B. Spetzler · 1 shared paper, 2026 · strength 0.24
- Peter J. Hosein · 1 shared paper, 2026 · strength 0.24
- Tanios Bekaii‐Saab · 1 shared paper, 2026 · strength 0.24
- Igor A. Astsaturov · 1 shared paper, 2026 · strength 0.24
- Michael Jon Pishvaian · 1 shared paper, 2026 · strength 0.24
- Daniel D. Von Hoff · 1 shared paper, 2026 · strength 0.24
- Valerie Gunchick · 1 shared paper, 2024 · strength 0.23
- Vaibhav Sahai · 1 shared paper, 2024 · strength 0.23
- Steve H. Kim · 1 shared paper, 2025 · strength 0.17
- Davendra P. S. Sohal · 1 shared paper, 2025 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.